American Association for Cancer Research
21598290cd110130-sup-cd-11-0130_supp_table_3.pdf (635.17 kB)

Supplementary Table 3 from Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets

Download (635.17 kB)
journal contribution
posted on 2023-04-03, 20:22 authored by Himisha Beltran, David S. Rickman, Kyung Park, Sung Suk Chae, Andrea Sboner, Theresa Y. MacDonald, Yuwei Wang, Karen L. Sheikh, Stéphane Terry, Scott T. Tagawa, Rajiv Dhir, Joel B. Nelson, Alexandre de la Taille, Yves Allory, Mark B. Gerstein, Sven Perner, Kenneth J. Pienta, Arul M. Chinnaiyan, Yuzhuo Wang, Colin C. Collins, Martin E. Gleave, Francesca Demichelis, David M. Nanus, Mark A. Rubin

PDF file - 635K



Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer that most commonly evolves from preexisting prostate adenocarcinoma (PCA). Using next-generation RNA sequencing and oligonucleotide arrays, we profiled 7 NEPC, 30 PCA, and 5 benign prostate tissue (BEN) samples and validated findings in tumors from a large cohort of patients (37 with NEPC, 169 with PCA, and 22 with BEN) using immunohistochemistry and FISH. We discovered significant overexpression and gene amplification of AURKA and MYCN in 40% of NEPC and 5% of PCA tumors, respectively, and evidence that they cooperate to induce a neuroendocrine phenotype in prostate cells. There was dramatic and enhanced sensitivity of NEPC (and MYCN overexpressing PCA) to Aurora kinase inhibitor therapy both in vitro and in vivo, with complete suppression of neuroendocrine marker expression following treatment. We propose that alterations in Aurora kinase A and N-myc are involved in the development of NEPC and that future clinical trials will help determine the efficacy of Aurora kinase inhibitor therapy.Significance: We report on the largest in-depth molecular analysis of NEPC and provide new insight into molecular events involved in the progression of prostate cancer. Cancer Discovery; 1(6); 487–95. ©2011 AACR.Read the Commentary on this article by Aparicio et al., p. 466This article is highlighted in the In This Issue feature, p. 457

Usage metrics

    Cancer Discovery



    Ref. manager